Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study

Multicenter Insights on Real-World Results Of Ropeginterferon Alpha-2B in Polycythemia Vera Patients

NCT07282132•Federico II University

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Polycytemia Vera

Interventions

Ropeginterferon alfa-2b (BESREMi®)

Key Dates

Start Date

January 10, 2026

Primary Completion Date

March 26, 2026

Completion Date

March 31, 2026

Last Updated

December 15, 2025

Contacts

Novella Pugliese, MD, PhD

CONTACT

+393396137232 novypugliese@yahoo.it

Sponsors

Lead Sponsor

Federico II University

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions